

**Editor Board of
Trend in
Bio/Pharmaceutical
Industry**

Editor in Chief

John Wang
Novartis, USA

Board of Scientific Editors

Feng Gen-sheng
Burnham Inst.
USA

Han Jun
Novartis, USA

Li Bin
Chempartner, China

Li Hui
Pfizer, USA

Li Leping
Amgen, USA

Liu Chuan
J&J, USA

Mo Chengjun
Medimmune, USA

Shi Li
Merck, USA

Wang Deqian
Bayer, USA

Wei Yingfei
Elixirin, USA

Wu Jinzi
Ambrilia, Canada

Wu Ruifang
CJND, China

Yang Dajun
Ascera, USA

Yang Pei
Sunesis, USA

Yang Naibo
MDS, USA

Yu Guoliang
Epitomics, USA

Art Director

Li Xiaojun
CA State, USA

TBI online
www.cabsweb.org

Contact us:
TBI@CABSweb.org

Letter from Editor

Dear TBI readers,



It is my great pleasure to introduce this second issue of 2007 to you. Rooted deeply in the Chinese American biopharmaceutical community, our journal TBI has just reached a new stage of development.

First of all, TBI has a new sponsor. I would like to introduce to you our recently incorporated organization – Chinese American BioPharmaceutical Society (CABS). CABS is a nonprofit professional association headquartered in San Francisco, California. It was established to better serve our biopharmaceutical community in the region and to facilitate collaborations with like organizations in the US and abroad. CABS is very proud to

be the major sponsor of TBI. Please check the website www.CABSweb.org for the most recent issue of the journal.

Secondly, the publication of this issue coincided with Annual Conferences of several leading Chinese American pharmaceutical and life science organizations from coast to coast. TBI provides a shared platform for Chinese American professional organizations. This issue reported five very successful Annual Conferences from major biopharmaceutical centers in the US – San Francisco, San Diego (SABPA), Washington DC (CBA), Philadelphia (SAPA-GP) and Boston (SAPA-NE). It is of great interest to note that almost all the conferences have had a similar theme: “globalization”. However, this time, the key message about such rapidly evolving globalization is not on CRO but is right about pharmaceutical R&D. China, in particular, is emerging as both a huge market and a R&D base for biopharmaceutical industry. As Dr. Daniel Vasella, chief executive of Novartis pointed out: “The level of scientific expertise in China is rising rapidly” and “At the same time, the health care needs of the Chinese are growing too”.

Is China ready for such change? The News Digest regarding scientific breakthroughs in China and the Report on the competitiveness of Chinese pharmaceutical industry should bring you a balanced view on the issue.

Besides the overwhelming theme on “globalization”, this issue is rich in scientific and business contents as well. It covers cutting edge researches on RNAi therapeutics, small molecule discovery, vaccine development, as well as discussions on FDA regulation and US patent law, etc.

TBI is taking shape of a premium informational platform for biopharmaceutical industries in the US and China. There are tremendous opportunities in the budding Chinese industry. As an editor of TBI, I would like to invite you to join this historic trend, and to further contribute to the community and our journal through submitting, reviewing, and editing articles, providing financial support etc.

Please join us and be part of the future!

Naibo Yang, Ph.D.
Editor, TBI
President, CABS